Skip to main content
Subscribe
Log In
More
Log in via Institution
Log in via OpenAthens
Log in via your Society
Select your society
ESGO
IGCS
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
Basket
Search
More
Search for this keyword
Advanced search
Latest content
Current issue
Archive
Authors
About
YouTube
Podcasts
Zoom Journal Club
Search for this keyword
Advanced search
Close
More
Main menu
Latest content
Current issue
Archive
Authors
About
YouTube
Podcasts
Zoom Journal Club
Subscribe
Log in
More
Log in via Institution
Log in via OpenAthens
Log in via your Society
Select your society
ESGO
IGCS
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
BMJ Journals
You are here
Home
Recurrent advanced ovarian cancer
Email alerts
Recurrent advanced ovarian cancer
The Pharmacological Costs of Second-Line Treatments for Recurrent Ovarian Cancer
Jacopo
Giuliani
,
Andrea
Bonetti
International Journal of Gynecologic Cancer
Nov 2017,
27
(9)
1872-1876;
DOI:
10.1097/IGC.0000000000001106
Special collections
Editor's choice
(187)
Guidelines, Recommendations and Consensus Statements
IJGC
Case Study
(17)
Cervical Cancer
(20)
Clinical Trial
(107)
Corners of the World
(23)
Endometrial Cancer
Fertility and Pregnancy
Lay summaries
(1)
Lead articles
(13)
Ovarian Cancer
(35)
Palliative Care
Perioperative Care
Preinvasive Disease
(1)
Review
(28)
Surgical Outcomes
Uterine Cancer
(16)
Video Article
(176)
Vulvar Cancer
(2)
Open access
(266)
Press releases
(4)